| Literature DB >> 19352104 |
Abstract
Systemic treatment, including monoclonal antibodies against tumor-associated targets, has increased the median survival of patients with metastatic colorectal cancer over 100% in the past few years. The prolonged life-span of these patients has led to the development of new and unusual complications that were typically not seen in the era of 5-fluorouracil and leucovorin. A multidisciplinary approach is now more crucial than ever. In this report, we will discuss a patient who presented with a metastatic lesion nearly obstructing the small bowel three years following the diagnosis of metastatic colon cancer.Entities:
Year: 2009 PMID: 19352104 DOI: 10.1097/01.cad.0000349758.87244.02
Source DB: PubMed Journal: Anticancer Drugs ISSN: 0959-4973 Impact factor: 2.248